{"id":"NCT00910910","sponsor":"Celgene","briefTitle":"Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)","officialTitle":"A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (RevlimidÂ®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10-13","primaryCompletion":"2014-03-31","completion":"2018-05-09","firstPosted":"2009-06-01","resultsPosted":"2016-12-21","lastUpdate":"2019-07-09"},"enrollment":450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["B-Cell Chronic Lymphocytic Leukemia"],"interventions":[{"type":"DRUG","name":"Lenalidomide","otherNames":["Revlimid"]},{"type":"DRUG","name":"Chlorambucil","otherNames":["Leukeran"]}],"arms":[{"label":"1 - Lenalidomide","type":"EXPERIMENTAL"},{"label":"2- Chlorambucil","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil.","primaryOutcome":{"measure":"Kaplan-Meier Estimate of Progression Free Survival (PFS)","timeFrame":"From first dose of study drug to date of data cut-off of 18 Feb 2013; up to approximately 39 months","effectByArm":[{"arm":"Lenalidomide","deltaMin":30.8,"sd":null},{"arm":"Chlorambucil","deltaMin":23,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.323"}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":165,"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","Colombia","Croatia","Czechia","Denmark","France","Hungary","Israel","Italy","Netherlands","New Zealand","Poland","Portugal","Romania","Russia","Serbia","Slovakia","South Africa","Spain","United Kingdom"]},"refs":{"pmids":["28140392"],"seeAlso":["https://www.nature.com/articles/leu201747"]},"adverseEventsSummary":{"seriousAny":{"events":148,"n":224},"commonTop":["NEUTROPENIA","THROMBOCYTOPENIA","FATIGUE","ANAEMIA","DIARRHOEA"]}}